Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03647540
Other study ID # 130020
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 30, 2018
Est. completion date August 30, 2022

Study information

Verified date April 2020
Source Jilin University
Contact Dong Yang, Master
Email 714488468@qq.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The fluorescent laparoscopic technique would be applied to the radical resection of gastric cancer at the junction of esophagus and stomach, and compared with the traditional laparoscopic radical resection of gastric cancer to find a better surgical method for patients


Recruitment information / eligibility

Status Recruiting
Enrollment 164
Est. completion date August 30, 2022
Est. primary completion date June 30, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- 1. All cases should be diagnosed as adenocarcinoma of the esophagogastric junctionncer by histology. The tumor is within 1 cm above or 2 cm below the anatomic cardia. The clinical stage is T1-3, Nx, M0 for gastric cancer which can undergo the laparoscopic surgery.

2. Eastern Cooperative Oncology Group (ECOG) scale 0-2 3. Heart, lung, liver, and kidney function can tolerate operation 4. Patients and their families are able to understand and be willing to participate in this clinical study and to sign informed consent.

Exclusion Criteria:

1. history of stomach malignant disease 2. recent diagnosis of other malignant tumors (except for papillary carcinoma of the thyroid gland and basal cell carcinoma of the skin) 3. patients with obstruction, perforation, bleeding requiring emergency surgery 4. a history of abdominal surgery (which makes it difficult to perform laparoscopic procedures), severe systemic disease such as diabetes, severe chronic lung disease, cirrhosis, other malignant diseases 5. combined stomach multiple carcinomas 6. with a history of serious mental illness 7. pregnant or lactating women 8. The researchers believe that the patients are unsuitable to participate in the researchers with other cases.

-

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
fluorescent laparoscopic radical gastrectomy
The gastrectomy for group F would be underwent by the fluorescence laparoscopy. All surgical procedures will be performed by the surgery team ,which is leaded by professor Wang Quan.
traditional laparoscopic radical gastrectomy
The gastrectomy for group L would be underwent by the laparoscopy.All surgical procedures will be performed by the surgery team ,which is leaded by professor Wang Quan.

Locations

Country Name City State
China the First Hospital of Jilin University Ch'ang-ch'un Ji Lin

Sponsors (1)

Lead Sponsor Collaborator
Dong Yang

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary the number of the dissected lymph nodes It includes the total number of the dissected lymph nodes and every group of lymph nodes in the perioperative period
Secondary 3-year disease-free survival three years after operation]
Secondary the incidence of complications one month after surgery
Secondary the operation time The descriptive name of unit would be minute (min). in the perioperative period
Secondary the blood loss during the operation The descriptive name of unit would be millilitre (ml). in the perioperative period
Secondary Postoperative recovery of intestinal peristalsis The descriptive name of unit would be hour (h). in the perioperative period
Secondary cases converted to open surgery in the perioperative period
Secondary The mean postoperative hospital stay The descriptive name of unit would be day (d). in the perioperative period
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04062656 - Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG Phase 2
Completed NCT05419349 - Novel Staging Schemes for Siewert Type II Esophagogastric Junction Adenocarcinoma: A Real-World Data Cohort Study From SEER Database
Active, not recruiting NCT02509286 - Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus Phase 3
Completed NCT00849615 - Prospective Study With FLOT in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction Phase 2
Completed NCT02287129 - Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction Phase 2
Completed NCT00737373 - Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer Phase 2